Get the Stockscreener App
0.0576
52.00%
-0.0624
Bio Path Holdings Inc stock is traded at $0.0576, with a volume of 327.35K.
It is down -52.00% in the last 24 hours and down -80.61% over the past month.
See More
Previous Close:
$0.12
Open:
$0.0567
24h Volume:
327.35K
Relative Volume:
60.50
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.08M
P/E Ratio:
-0.00167
EPS:
-34.43
Net Cash Flow:
$-11.54M
1W Performance:
-52.00%
1M Performance:
-80.61%
6M Performance:
-86.27%
1Y Performance:
-97.18%
1-Day Range:
$0.0567
$0.062
1-Week Range:
$0.0567
$0.062
52-Week Range:
$0.0567
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.0576 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
What’s the recovery path for long term holders of bluebird bio Inc.Earnings Overview Report & Accurate Technical Buy Alerts - newser.com
What’s the recovery path for long term holders of Tevogen Bio Holdings Inc. Equity WarrantJuly 2025 Fed Impact & Verified Momentum Watchlists - Newser
What’s the recovery path for long term holders of Nuvation Bio Inc.2025 Breakouts & Breakdowns & Technical Pattern Based Signals - Newser
Marginal Zone Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential - openPR.com
Tevogen Bio Holdings Inc. stock trend outlook and recovery pathJuly 2025 Technicals & Entry Point Strategy Guides - Newser
What’s the recovery path for long term holders of Korro Bio Inc.Analyst Upgrade & Technical Pattern Based Signals - Newser
RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - Barchart.com
RNA Interference Pipeline Outlook 2025: Clinical Trial - openPR.com
TELA Bio Inc. stock trend outlook and recovery pathVolume Spike & AI Driven Price Forecasts - Newser
What’s the recovery path for long term holders of Tenable Holdings Inc.2025 Short Interest & Low Drawdown Investment Strategies - Newser
What’s the recovery path for long term holders of Torrid Holdings Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - Newser
What’s the recovery path for long term holders of Tian Ruixiang Holdings LtdRisk Management & Expert Approved Momentum Trade Ideas - Newser
Applying chart zones and confluence areas to Tevogen Bio Holdings Inc.Layoff News & Scalable Portfolio Growth Methods - Newser
Zimmer Biomet Holdings Inc. stock trend outlook and recovery path2025 Technical Overview & Weekly Watchlist for Hot Stocks - Newser
Pattern recognition hints at Tevogen Bio Holdings Inc. upsideTrade Ideas & Expert Curated Trade Ideas - Newser
What’s the recovery path for long term holders of Sportsman s Warehouse Holdings Inc.2025 Price Momentum & Weekly High Return Stock Forecasts - Newser
What’s the recovery path for long term holders of Post Holdings Inc.July 2025 Reactions & Community Supported Trade Ideas - Newser
Antisense Oligonucleotide Therapeutics Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail
What’s the recovery path for long term holders of Thermon Group Holdings Inc.Trade Entry Summary & Verified Short-Term Trading Plans - Newser
What’s the recovery path for long term holders of Mobix Labs Inc. Equity Warrant2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
What’s the recovery path for long term holders of KVACW2025 Year in Review & Free High Accuracy Swing Entry Alerts - Newser
What’s the recovery path for long term holders of Zimmer Biomet Holdings Inc.Trade Signal Summary & AI Forecasted Entry/Exit Points - Newser
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire
What’s the recovery path for long term holders of Bio Rad Laboratories Inc.July 2025 Momentum & Low Drawdown Momentum Ideas - Newser
What’s the recovery path for long term holders of INmune Bio Inc.July 2025 Volume & Low Drawdown Investment Ideas - Newser
Post Holdings Inc. stock trend outlook and recovery pathMarket Risk Summary & Technical Confirmation Alerts - Newser
Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - MSN
North American Morning Briefing : Stock Futures -2- - MarketScreener
FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight - The Malaysian Reserve
Third Harmonic Bio Inc. stock trend outlook and recovery pathQuarterly Investment Review & Weekly High Potential Alerts - Newser
Tevogen Bio Holdings and the Path to Revenue by 2026: A Strategic Assessment of Risk, Innovation, and Capital Efficiency - AInvest
Bio-Path: Q2 Earnings Snapshot - Stamford Advocate
Bio-Path Holdings: Navigating Financial Turbulence with Promising RNAi Innovation - AInvest
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
Korro Bio Inc. stock trend outlook and recovery pathJuly 2025 Levels & Technical Entry and Exit Tips - Newser
What’s the recovery path for long term holders of Palisade Bio Inc.2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Bio-Path (BPTH) Projected to Post Earnings on Thursday - Defense World
Bio-Path Holdings dismisses Ernst & Young as auditor, seeks new firm - Investing.com Nigeria
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.53%
Cap:
|
Volume (24h):